Supplementary

Appendix 1

Data dictionary

Initial diagnosis	Required data (definition/comment)
Patient age	Years (whole years at the time of diagnosis)
2. Patient sex	Male/Female
3. Charlson Comorbidity Index	Myocardial infarct/Heart failure/Peripheral vascular disease/CVA or TIA/Dementia/COPD/ Connective tissue disorder/Peptic ulcer disease/liver disease/Diabetes Mellitus/Hemiplegia/ Moderate to severe CKD/Leukaemia/Lymphoma/AIDS
4. What is the site of the cancer?	Oesophagus (proximal/middle/distal)/GEJ /Stomach (proximal/body/antrum/pylorus)
Was patient being managed within a Barrett's oesophagus surveillance programme?	No/Yes
Any history of dysplasia within Barrett's?	No/Yes
7. Any previous history of anti-reflux surgery?	No/Yes
8. Any current relevant medications?	PPI/H2 antagonist/aspirin
Findings at diagnostic gastroscopy	Hiatus hernia/Barrett's (Prague C M) Site of lesion (cm from incisors) Size of lesion (mm)
10.Biopsy histology	Adenocarcinoma/squamous cell carcinoma/HGD/Other
11.Additional staging investigations	CT/PET/EUS/Staging laparoscopy (tick all that apply)

Treatment	Required data (definition/comment)
Index treatment received	None/Endoscopic resection/Surgical resection/oncological treatment -> If any treatment other than endoscopic: What was pre-treatment staging? T1aN0/T1bN0 (sm1/sm2-3/sm not reported)/HGD

Endoscopic resection	Required data (definition/comment)
Type of Endoscopic resection	EMR/ESD
2. Complications	Bleeding requiring reintervention or transfusion/Perforation/sedation or drug related/other/ None
3. Histological outcome	Grade: LGD/HGD/T1a (m1/m2/m3/m not reported)/T1b (if T1b then option for sm1 (<=500um)/ >sm1 (>500um)/sm invasion depth not reported)/>T1b If ESD: Malignant involvement of circumferential margin? y/n/equivocal or unclear/not reported Malignant involvement of deep margin? y/n/equivocal or unclear/not reported Lymphovascular invasion? y/n/ not reported Differentiation (select worst option if mixed type)? well/moderate/poor/not reported Signet ring cells? y/n
Recommended management after endoscopic resection	

Endoscopic surveillance	Required data (definition/comment)
Was additional endoscopic treatment to remaining areas of Barretts performed	Argon plasma coagulation/radiofrequency ablation/ cryoablation/ PDT/no/other (please state)/n/a (no Barretts)
Was any routine imaging used as part of the surveillance program?	No/CT/PET/EUS (select all that apply)
Was any local recurrence of cancer diagnosed at any point?	If yes -> →Was this diagnosed as part of a routine endoscopic follow-up programme? → How many months from original endoscopic resection to diagnosis of recurrence? -> What clinical stage was the cancer recurrence diagnosed at? T1a/b/2/3/4 N1/2/3 M0/1 -> Was any further intervention undertaken to treat recurrence with curative intent? endoscopic resection/surgery +/- oncological therapy/chemotherapy only/radiotherapy only/ chemoradiotherapy only then go to appropriate logic branch If no -> follow-up outcomes logic branch

Radiological surveillance only	Required data (definition/comment)
What imaging was used as part of the surveillance program?	No/CT/PET (select all that apply)
Was any local recurrence of cancer diagnosed at any point?	If yes -> Was this diagnosed as part of a routine radiological follow-up programme? → How many months from original endoscopic resection to diagnosis of recurrence? -> What clinical stage was the cancer recurrence diagnosed at? T1a/b/2/3/4 N1/2/3 M0/1 -> Was any further intervention undertaken to treat recurrence with curative intent? endoscopic resection/surgery +/- oncological therapy/chemotherapy only/radiotherapy only/ chemoradiotherapy only then go to appropriate logic branch If no -> follow-up outcomes logic branch

Definitive oncological treatment	
Primary modality	Chemotherapy/chemoradiotherapy/radiotherapy [then offer appropriate options from below]
2. Chemotherapy agent	Carboplatin/paclitaxel (i.e. as part of CROSS) 5FU, leucovorin, oxaliplatin, docetaxel (FLOT) Cisplatin/capecitabine Cisplatin and capecitabine/5FU Carboplatin and capecitabine/5FU Oxaliplatin and capecitabine/5FU Epirubicin, cisplatin, capecitabine Other (freetext)
3. Radiotherapy	External beam radiotherapy 41.4 Gy (CROSS) External beam radiotherapy 45 Gy External beam radiotherapy 50 Gy External beam radiotherapy 54 Gy External beam radiotherapy 60 Gy Brachytherapy 10 Gy Brachytherapy 15 Gy Other

Curative Surgery	
Neoadjuvant therapy	Did the patient receive neoadjuvant treatment? y/n [offer below options if y]
2. Neoadjuvant chemotherapy	None Carboplatin/paclitaxel (e.g. CROSS) 5FU, leucovorin, oxaliplatin, docetaxel (FLOT) Cisplatin/capecitabine Cisplatin and capecitabine/5FU Carboplatin and capecitabine/5FU Oxaliplatin and capecitabine/5FU Epirubicin, cisplatin, capecitabine Other (freetext)
3. Neoadjuvant radiotherapy	External beam radiotherapy 41.4 Gy (CROSS) External beam radiotherapy 45 Gy External beam radiotherapy 50 Gy External beam radiotherapy 54 Gy External beam radiotherapy 60 Gy
4. Operation type	2-stage IL/3-stage/Transhiatal/Thoracoabdominal/Proximal gastrectomy/Distal gastrectomy/ Total gastrectomy/Extended total gastrectomy
5. Abdominal approach	Open/Laparoscopic/Laparoscopic converted to open/Robotic/Robotic converted to laparoscopic/Robotic converted to open
6. Thoracic approach	Not applicable/Open/Laparoscopic/Laparoscopic converted to open/Robotic/Robotic converted to laparoscopic/Robotic converted to open
7. Post-operative length of stay (hospital)	Number (days between from the <u>first post-operative day</u> to <u>day of discharge</u> . If the patient has not been discharged prior to the end of 30-day follow-up, enter '31').
8. Highest 30-day complication grade	None/Grade I (does not require change to management)/Grade II (requiring medical or pharmaceutical management)/Grade IIIa (requiring endoscopic or radiological intervention)/Grade IIIb (requiring reoperation)/Grade IV (requiring unplanned intensive care admission)/Grade V (death)
9. Reoperation required	No/Yes
10.Unplanned readmission by day 30	No/Yes

Postoperative Pathology Data Fields	Required data (definition/comment)
1. T stage	T0/T1a/T1b/T2/T3/T4 If T1a: m1, m2, m3, not reported If T1b: sm1, sm2-3, not reported
2. N stage	N0/N1/N2/N3
3. Lymph nodes examined	(number)
4. Lymph nodes positive	(number)
5. Proximal longitudinal margin	R0 (>1mm)/R1a (<1mm)/R1b (involved margin)/R2
6. Distal longitudinal margin	R0 (>1mm)/R1a (<1mm)/R1b (involved margin)/R2
7. Circumferential margin	R0 (>1mm)/R1a (<1mm)/R1b (involved margin)/R2
8. Lymphovascular invasion	No/Yes
9. Tumour differentiation	Well/Moderate/Poor/Anaplastic
10.Were any signet ring cells present?	No/Yes
11.Did the patient receive any adjuvant (post-operative) chemotherapy?	No/Yes
12.Did the patient suffer cancer recurrence at any point?	Yes -> how long between surgery and recurrence (months) No -> Then go to follow-up outcomes logic branch

Follow-up Outcomes Data Fields	Required data (definition/comment)
At last follow-up, what is the patients status?	Dead/Alive
What is the time duration from diagnosis to last known follow-up/death?	(months)